CD34?+ cell dose and outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation

REFERENCES

• Pérez-Simón JA, Martin A, Caballero D, Corral M, Nieto MJ, Gonzalez M, et al. Clinical significance of CD34 + cell dose in long term engraftment following autologous periph-eral blood stem cell transplantation. Bone Marrow Transplantation 1999;24: 1279 —1283.
   Google Scholar
• Kiss JE, Rybka WB, Winkelstein A, deMagalhaes-SilvermanM, Lister J, D'Andrea P, Ball ED. Relationship of CD34 + cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation 1997;19: 303 —310.
   Google Scholar
• Urbano-Ispizua A. High stem cell dose in hemopoietic transplantation: is it always beneficial? Leukemia 2003;17:1467–1469.
   Google Scholar
• Bittencourt H, Rocha V, Chevret S, Socié G, Esperou H, Devergie A, et al. Association of CD 34 cell dose with hematopoietic recorvery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002;99: 2726— 2733.
   Google Scholar
• Dominietto A, Lamparelli T, Raiola AM, Van Lint MT, Gualandi F, Berisso G, et al. Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogenic marrow transplan-tation. Blood 2002;100:3930–3994.
   Google Scholar
• Rocha V, Labopin M, Gluckman E, Powles R, Arcese W, Bacigalupo A, et al. Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukemia in first complete remission: results of a European survey. Journal of Clinical Oncology 2002;20:4324–4330.
   Google Scholar
• Mavroudis D, Read E, Cottler-Fox M, Couriel D, Molldrem J, Carter C, et al. CD 34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malig-nancies. Blood 1996;88: 3223–3229.
   Google Scholar
• Sierra J, Storer B, Hansen J, Bjerke JW, Martin PJ, Petersdorf EW, et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA matching and marrow cell dose. Blood 1997;89:4226–4235.
   Google Scholar
• Schmitz N, Beksac M, Hasenclever D, Bacigalupo A, Ruutu T, Nagler A, et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standar-risk leukemia. Blood 2002;100:761–767.
   Google Scholar
• Przepiorka D, Smith TL, Folloder J, Khouri I, Ueno NT, Mehra R, et al. Risk factors for acute graft-versus-host disease after allogenic blood stem cell transplantation. Blood 1999;94:1465 — 1470.
   Google Scholar
• Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khouri I, et al. Chronic graft-versus-host-disease after allogeneic blood stem cell transplantation. Blood 2001;98:1695 — 1700.
   Google Scholar
• Zaucha JM, Gooley T, Bensinger WI, Heimfeld S, Chauncey TR, Zaucha R, et al. CD 34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engrafment kinetics and development of extensive cronic graft-versus-host disease after human leucocyte antigen-identical sibling transplantation. Blood 2001;98:3221 —3227.
   Google Scholar
• Mothy M, Bilger K, Jourdan E, Kuentz M, Michallet M, Bourhis JH, et al. Higher doses of CD34 + peripheral blood stem cells are associated with increased mortality from chronic graft versus host disease after allogeneic HLA identical sibling transplantation. Leukemia 2003;17:869 — 875.
   Google Scholar
• Urbano-Ispizua A, Carreras E, Main P, Rovira M, Martinez C, Fernandez-Aviles F, et al. Allogeneic transplantation of CD 34( +) selected cells from peripheral blood from human leukocyte antigen-identical siblings: detrimental effect of a high number of donor CD 34( +) cells? Blood 2001;98: 2352–2357.
   Google Scholar
• Heimfeld S. HLA identical stem cell transplantation: is there an optimal CD34 cell dose? Bone Marrow Transplantation 2003;31:839 — 845.
   Google Scholar
• Pérez-Simón JA, Diez-Campelo M, Martino R, Sureda A, Caballero D, Canizo C, et al. Impact of CD34 + cell dose on the outcome of patients undergoing reduced intensity conditioning allogeneic peripheral blood stem cell transplan-tation. Blood 2003;102:1108–1113.
   Google Scholar
• Carvallo C, Séller N, Kurlander R, Srinivasan R, Mena 0, Igarashi T, et al. Prior chemotherapy and allograft CD34 + dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors. Blood 2004;103: 1560–1563.
   Google Scholar
• Thomson K, Ings S, Watts M, Mackinnon S, Peggs KS. CD34 + cell dose and the ocurrence of GVHD in the presence of in vivo T-cell depletion. Blood 2004;103: 743.
   Google Scholar
• Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs. -host disease. Biology Blood Marrow Transplantation 1999;5:347–356.
   Google Scholar
• Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: pathobiology and management. Experimental He-matology 2001;29:259— 277.
   Google Scholar
• Teshima T, Ferrara JL. Pathogenesis and prevention of acute graf-versus-host-disease. Current Opinion in Organ Trans-plantation 2001;6:265–271.
   Google Scholar
• Cooke KR, Hill GR, Gerbitz A, Kobzik L, Martin TR, Crawford JM, et al. Tumor necrosis factor-alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. Journal of Clinical Investigation 1998;102:1882 — 1891.
   Google Scholar
• Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997;90:3204–3213.
   Google Scholar
• Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation [review]. Blood 2000;95:2754–2759.
   Google Scholar
• Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor a during graft-versus-host disease. Journal Experimental Medicine 1992;175:405— 413.
   Google Scholar
• Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, busulfan-cyclopho-sphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994;83: 2360–2367.
   Google Scholar
• Blaise D, Kuentz M, Fortanier C, Bourhis JH, Milpied N, Sutton L, et al. Randomized trial of Bone Marrow versus Lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. Journal of Clinical Oncology 2000;18:537 — 546.
   Google Scholar
• Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. New England Journal of Medicine 2001;344:175— 181.
   Google Scholar
• Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J, et al. Allogenic blood and bone marrow stem cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000;355:1231–1237.
   Google Scholar
• Schmitz N, Beksac M, Hasenclever D, Bacigalupo A, Ruutu T, Nagler A, et al. Transplantation of mobilized peripheral blood cells to HLA identical siblings with standard risk leukemia. Blood 2002;100:761 —767.
   Google Scholar
• Cutler C, Girl S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH. Acute and chronic graft versus host disease after allogeneic peripheral blood stem cell and bone marrow transplantation: a meta-analysis. Journal of Clinical Oncology 2001;19:3685–3691.
   Google Scholar
• Kernan NA, Collins NM, Juliano L, Cartagena T, Dupont B, O'Reilly RJ. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of GVHD. Blood 1986;68:770–773.
   Google Scholar
• Theilgaard-Monch K, Raaschou-Jensen K, Schjodt K, Hellmann C, Vindelov L, Jacobsen N, et al. Pluripotent and myeloid committed CD34 + subsets in hematopoietic stem cell allograft. Bone Marrow Transplant 2003;32:1125 — 1133.
   Google Scholar
• Menéndez P, Pérez-Simón JA, Mateos MV, Caballero MV, Gonzalez M, San Miguel JF, Orfao A. Influence of the different CD34 + and CD34- cell subsets infused on the clinical outcome of non-myeloablative allogeneic peripheral blood transplantation from HLA identical sibling donors. British Journal of Haematology 2002;119:135–143.
   Google Scholar
• Ryncarz RE, Anasetti C. Expression of CD86 on human marrow CD34( +) cells identifies immunocompetent com-mitted precursors of macrophages and dendritic cells. Blood 1998;91:3892 —3900.
   Google Scholar
• Bacigalupo A, Frassoni F, van Lint MT. Bone of marrow CFU-GM content on engraftment and survival after allo-genic bone marrow transplantation. Bone Marrow Transplantation 1995;15:221–226.
   Google Scholar
• Pan L, Delmonte J Jr, Jalonen CK, Ferrara JL. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995;86:4422— 4429.
   Google Scholar
• Mielcarek M, Roecklein BA, Torok-Storb B. CD 14 + cells in granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood mononuclear cells induce secretion of interleukin-6 and G-CSF by marrow stroma. Blood 1996;87: 574–580.
   Google Scholar
• Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T-helper 2-inducing dendritic cells. Blood 2000;95: 2484–2490.
   Google Scholar
• Urbano-Ispiuza A, Rozman C, Martinez C, Marin P, Briones J, Rovira M, et al. Rapid engraftment without significant GVHD after allogeneic transplantation of CD 34+ selected cells from peripheral blood. Blood 1997;89: 3967 —3973.
   Google Scholar
• Urbano-Ispizua A, Rozman C, Pimentel P, Solano C, de la Rubia J, Brunet S, et al. The number of donor CD3( +) cells is the most important factor for graft failure after allogeneic transplantation of CD34( +) selected cells from peripheral blood from HLA-identical siblings. Blood 2001;97: 383 — 387.
   Google Scholar
• Chen B, Cui X, Sempowski G, Domen J, Chao NJ. Hematopoietic stem cell dose correlates with the speed of immune reconstitution after stem cell transplantation. Blood 2004;103:4344 — 4352.
   Google Scholar
• Pérez-Simón JA, Caballero D, Diez-Campelo M, López-Pérez R, Mateos G, Cañizo C, et al. Chimerism and minimal residual disease monitoring after reduced intensity condition-ing (RIC) allogeneic transplantation. Leukemia 2002;16:1423— 1431.
   Google Scholar
• Valcárcel D, Martino R, Caballero D, Mateos MV, Peréz-Simon JA, Canals C, et al. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplanta-tion 2003;31:387–392.
   Google Scholar
• Anderson B, McNiff J, Matte C, Athanasiadis I, Shlomchik WD, Shlomchik MJ, et al. Recipient CD4+ T cells that survive irradiation regulate chronic graft-vs. -host disease. Blood 2004;104:1565— 1573.
   Google Scholar
• Petersen S, Madsen H, Ryder L, Svejgaard A, Masmas TN, Dickmeiss E, et al. Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8+ T-cell count on day + 14 as a predictor of acute graft-versus-host disease. Biology Blood and Marrow Transplantation 2004;10:337 —347.
   Google Scholar